Biogen likely to come up empty despite getting its two Alzheimer's drugs approved
www.alzheimers-information.org
The FDA recently rush-approved two Biogen drugs aimed at reducing the presence of amyloid proteins in the brain. Amyloid proteins were previously thought to be the cause of Alzheimer’s disease but that concept has basically fallen apart in recent years. Not only have ~16 drugs that reduce the presence of the protein failed to reduce the effects of Alzhiemer’s but it turns out that
Biogen likely to come up empty despite getting its two Alzheimer's drugs approved
Biogen likely to come up empty despite…
Biogen likely to come up empty despite getting its two Alzheimer's drugs approved
The FDA recently rush-approved two Biogen drugs aimed at reducing the presence of amyloid proteins in the brain. Amyloid proteins were previously thought to be the cause of Alzheimer’s disease but that concept has basically fallen apart in recent years. Not only have ~16 drugs that reduce the presence of the protein failed to reduce the effects of Alzhiemer’s but it turns out that